[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatoid-arthritis-ra\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatoid-arthritis-ra":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,118,0,25,[9,52,85,108,136,162,193,215,240,265,288,315,341,364,407,435,462,483,502,523,564,589,610,630,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100629321","phase-1-controlling-hyperactive-immunity-with-long-lived-lymphocytes-100629321",false,"NCT07473154","Controlling Hyperactive Immunity With Long-lived Lymphocytes","Phase I\u002FII Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).","CHILL","Inclusion Criteria:\n\n* Participants must be at least 18 years of age at the time of signing the informed consent.\n* Up to date vaccination status and no planned vaccinations for post 3 months infusion\n* Adequate haematological, liver and renal function\n* Willing to undergo annual influenza vaccination\n* Willing to enter a 15-year follow-up\n* Eastern Cooperative Oncology Group (ECOG) performance status grade \\\u003C 3\n* Able and willing to use a highly effective method of contraception\n* Stable dose of steroid prior to screening\n\nSpecific inclusion criteria for participants with difficult to treat rheumatoid Arthritis (D2TRA) only:\n\n* Diagnosis of Rheumatoid Arthritis (RA) per 2010 ACR-EULAR criteria\n* Diagnosis of D2TRA per 2021 EULAR criteria\n* Evidence of clinically active disease a defined by validated clinical or laboratory results consistent with standard definitions of active RA\n* Evidence of inflammation in target joints used for the DAS28 CRP assessment\n\nSpecific inclusion criteria for participants with diffuse cutaneous systemic sclerosis (dcSSc) only:\n\n* Diagnosis of dcSSc as per the 2013 ACR-EULAR criteria\n* Serologically positive for antinuclear antibodies\n* Failure to respond sufficiently to immunomodulatory disease modifying anti-rheumatic drugs (DMARDs).\n* Skin involvement with a total modified Rodnan Skin Score of at least 15\n* Evidence of lung fibrosis based on imaging or pulmonary function testing\n* Evidence of active disease based on a validated SSc activity assessment\n\nExclusion Criteria:\n\n* Presence of a significant medical condition(s), or clinically significant laboratory abnormality\n* History or concern of autoimmune diseases other than those under study\n* Active infection, or recurrent chronic infection requiring intervention\n* Immunodeficiency or receiving immunoglobulin replacement therapy\n* Past or current infection with hepatitis B or C, tuberculosis, syphilis, or HIV\n* Clinically significant cardiac dysfunction or severe pulmonary impairment\n* Use of investigational agents within a pre-defined period prior to study screening\n* Received a previous cell therapy\n* Received certain B cell related experimental therapies in a clinical trial with the past year\n* Any solid organ, bone marrow or stem cell transplant\n* History of malignancy in the past 5 years\n* Receiving prohibited medication that cannot be stopped at screening","ALL","18 Years",{"count":21,"type":22},16,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This study is a Phase 1\u002F2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether QEL-005 is safe, how well people tolerate it, and whether it may help reduce disease activity or improve symptoms.\n\nQEL-005 is made from a participant's own white blood cells (autologous cells). These cells are collected and then changed in a laboratory using genetic methods to create specialized immune cells called CAR-T regulatory cells that target a protein on B cells called CD19. These modified cells are then given back to the participant by intravenous (IV) infusion.\n\nTo take part, eligible participants will first have a procedure called leukapheresis, where some of their white blood cells are removed from the blood. The study team will use these cells to manufacture QEL005. After QEL005 is ready, participants will receive an IV infusion of their modified cells, stay in hospital overnight for monitoring, and will then be followed closely in the clinic.\n\nThroughout the trial, participants will have regular safety checks, which may include blood tests, imaging scans, questionnaires about symptoms and daily functioning, and biopsies taken from involved tissues, to help understand how QEL005 is working in the body. Detailed follow up will be for 1 year after QEL-005 infusion, and there is long-term follow up for a total of 15 years, which is standard for cell therapies. The information from this Phase 1\u002F2 study will help determine an appropriate dose and dosing schedule of QEL005 for future studies.",[29,30,31,32],"Diffuse Cutaneous Systemic Sclerosis","Rheumatoid Arthritis (RA)","Systemic Sclerosis (SSc)","Autoimmune Rheumatologic Disease",[34,35,36,37,38],"Regulatory T cells","Autologous","Genetically modified cells","Treg","Chimeric antigen receptor (CAR)","RECRUITING","2026-08-20",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-04-10",{"date":47,"type":22},"2028-08",{"name":49,"class":50},"Quell Therapeutics Limited","INDUSTRY",10,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100652516","twenty-four-hour-movement-behaviors-and-atherosclerotic-risk-100652516","NCT07774507","Twenty-four Hour Movement Behaviors and Atherosclerotic Risk","Physical Activity, Sleep and Sedentary Behavior on Atherosclerotic Risk Outcomes Among People With Rheumatoid Arthritis","PASSARO","Inclusion Criteria:\n\n* Medical diagnosis of rheumatoid arthritis.\n* Age between 18 and 65 years.\n* Provide written informed consent.\n* Independence in daily living activities defined as a Katz Index score of 5 or 6 points.\n\nExclusion Criteria:\n\n* Acute infectious disease at the time of assessment.\n* Pregnancy or breastfeeding.\n* Cognitive impairment identified by the Mini-Mental State Examination according to established cutoff values.\n* History of cardiovascular disease, including coronary artery disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, or pulmonary embolism.\n* Use of uncontrolled vasoactive medication.\n* Inability to comply with accelerometer wear requirements.\n* Inability to complete study questionnaires or physical assessments.\n* Invalid accelerometer data according to the study wear-time criteria.","65 Years",{"count":62,"type":22},150,"1 Year","OBSERVATIONAL","This observational study aims to investigate how 24-hour movement behaviors are associated with atherosclerotic risk in adults with rheumatoid arthritis.\n\nThese behaviors include physical activity, sedentary behavior, and sleep.\n\nThe main questions it aims to answer are:\n\n* Are 24-hour movement behaviors, both individually and in combination, associated with indicators of atherosclerotic risk in adults with RA?\n* Do changes in 24-hour movement behaviors over 12 months relate to changes in indicators of atherosclerotic risk?\n\nParticipants will:\n\n* Wear activity monitors (accelerometers) continuously for 7 days to measure physical activity, sedentary behavior, and sleep.\n* Answer questionnaires about their health and lifestyle.\n* Undergo cardiovascular assessments, body composition measurements, physical fitness tests, and blood tests to measure lipid and inflammatory profile.\n* Return 12 months later for follow-up assessments.\n\nThe researchers hope this study will improve understanding of how daily movement behaviors influence cardiovascular health in people with rheumatoid arthritis. The findings may help inform future recommendations to promote healthier movement behaviors and improve cardiovascular risk management in this population.",[67,30,68],"Cardiovascular Risk Assessment","24-Hour Movement Guidelines",[70,71,72,73,74],"Rheumatoid Arthritis","Cardiovascular Health","Physical activity","Sleep","Sedentary behavior","2026-08-19",{"date":40,"type":43},{"date":78,"type":22},"2026-09-01",{"date":80,"type":22},"2028-06-30",{"name":82,"class":83},"São Paulo State University","OTHER",1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100652306","atherosclerosis-in-early-rheumatoid-arthritis-patients-using-atherogenic-index-of-the-plasma-and-carotid-intima-media-thickness-100652306","NCT07772466","Atherosclerosis in Early Rheumatoid Arthritis Patients Using Atherogenic Index of the Plasma and Carotid Intima Media Thickness","Atherogenic Index of Plasma and Carotid Intima-media Thickness as Predictors of Preclinical Atherosclerosis in Early Rheumatoid Arthritis Patients Younger Than 50 Years of Age","Inclusion Criteria:\n\nfor cases (Rheumatoid Arthritis patients)\n\n* Patients fulfilling the 2010 American College of Rheumatology \u002F European League Against Rheumatism (ACR\u002FEULAR) classification criteria for RA\n* Disease duration of ≤6 months from the onset of symptoms (early RA)\n\nFor Controls (Healthy Subjects):\n\n* Healthy volunteers aged 18 to 49 years with no known inflammatory, autoimmune, or chronic disease.\n* Age- and sex-matched (within ±2 years) to case subjects\n\nExclusion Criteria:\n\n* Established cardiovascular disease (coronary artery disease, prior myocardial infarction, stroke, peripheral arterial disease, or heart failure).\n* Diabetes mellitus, Hypertension, and Dyslipidaemia on lipid-lowering therapy (statins, fibrates, niacin, or omega-3 agents), as these agents directly modify AIP values.\n* Chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²) and Hepatic disease, thyroid dysfunction, or any other significant endocrine disorder.\n* Pregnancy or lactation.\n* Other connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome).\n* Other inflammatory arthropathies (psoriatic arthritis, ankylosing spondylitis, reactive arthritis).","50 Years",{"count":94,"type":22},70,"Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting the peripheral joints, yet its extra-articular burden particularly on the cardiovascular (CV) system has emerged as its most consequential long-term complication . Cardiovascular disease (CVD) accounts for 40% of all deaths in RA patients, making it the leading cause of mortality .This excess CV risk is estimated to be 1.5 to 2 times higher than in the general population .The overall CV risk conferred by RA has been linked in magnitude to that of diabetes mellitus, underscoring RA as an independent cardiovascular risk factor formally recognised in the 2021 European Society of Cardiology Guidelines on CVD prevention .\n\nIn this context, the non-invasive detection of preclinical atherosclerosis before the onset of clinical CV events has become clinical priority. Carotid intima-media thickness (CIMT), measured by high-resolution B-mode ultrasonography, is a well-validated surrogate marker of early structural arterial wall changes that independently predicts future myocardial infarction and stroke .Multiple studies have documented significantly elevated CIMT in RA patients compared with age- and sex-matched controls; studies found higher CIMT values across all age groups in RA, with values increasing in proportion to disease severity as assessed by the Disease Activity Score in 28 joints .\n\nThe atherogenic index of plasma (AIP) defined as the base-10 logarithm of the triglyceride-to-HDL-cholesterol ratio has emerged as a calculated composite biomarker reflecting lipoprotein particle atherogenicity, particularly the preponderance of small, dense LDL particles .A high AIP (\\>0.21) has been independently associated with major adverse cardiovascular events beyond the predictive capacity of conventional lipid panels .",[97,98],"Atheroscleroses","Rheumatoid Arthritis (RA","NOT_YET_RECRUITING","2026-08-16",{"date":75,"type":43},{"date":103,"type":22},"2026-10-01",{"date":105,"type":22},"2028-12-30",{"name":107,"class":83},"Assiut University",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":84},"100640639","phase-2-complementary-herbal-approach-to-rheumatoid-management-study-charms-100640639","NCT07627893","Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)","CHARMS","Inclusion Criteria:\n\n1. Patients between the ages of 21 and 70 years, and diagnosed with RA by a rheumatologist and fulfilling the 2010 ACR\u002FEULAR classification criteria for RA.\n2. Active disease with DAS28 ESR ≥3.2 at screening, with at least 6 swollen joints out of 66 and at least 6 tender joints out of 68.\n3. Receiving stable doses of methotrexate therapy for at least 3 months, and on stable dose for at least 4 weeks before trial entry ( ≥10mg per week), either subcutaneous or orally.\n4. Stable doses of non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, or oral corticosteroids (equivalent to prednisone ≤ 10 mg) for at least 4 weeks prior to first dose of study medication.\n5. Except for methotrexate, patients must have discontinued all csDMARDs, including, but not limited to: hydroxychloroquine, sulfasalazine, leflunomide prior to first dose of study medication as specified below:\n\n   1. ≥ 4 weeks prior to Baseline Visit for sulfasalazine and hydroxychloroquine\n   2. ≥ 8 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to an elimination procedure (i.e., 11 days with cholestyramine, or 30 days washout with activated charcoal)\n6. A negative urine pregnancy test for women of childbearing potential on Day 1 (prior to administration of first dose of study drug).\n7. Use of a reliable method of contraception by all female patients of childbearing potential and male patients with procreative capacity during the study and up to 3 months after the last dose of the study medication.\n\nExclusion Criteria:\n\n1. Not able to provide informed consent.\n2. Previous lack of efficacy to Si Miao Xiao Bi Tang.\n3. History of inflammatory joint disease other than RA. Secondary Sjogren's Syndrome is permitted.\n4. Concurrent use of other immunosuppressant medications, except MTX and protocol allowed doses of steroids.\n5. Has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point administration of corticosteroids in the preceding 4 weeks prior to the Baseline Visit.\n6. Subject has been treated with any investigational drug within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline Visit or is currently enrolling in another clinical study.\n7. Pregnant or breastfeeding females.\n8. Infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses, untreated malignancy, or evidence of active or untreated latent tuberculosis.\n9. Receipt of any live vaccine within 1 month prior to the Screening Visit, or expected need of live vaccination during study participation including up to 1 month after the last dose of study drug.\n10. History of clinically significant hematologic, pulmonary, renal, hepatic, or psychiatric disease that would interfere with the subject's participation in this study.\n11. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Day 1 or oral anti-infectives within 14 days prior to the Baseline Visit.\n12. Any uncontrolled clinically significant laboratory abnormality or any of the following laboratory abnormalities:\n\n    1. Evidence of hematopoietic disorder or hemoglobin \\\u003C9 g\u002FdL\n    2. White blood cell count \\\u003C3.0 x 10\\^9\u002FL (\\\u003C3000\u002Fmm\\^3)\n    3. Absolute neutrophil count \\\u003C1.2 x 10\\^9\u002FL (\\\u003C1000\u002Fmm\\^3)\n    4. Platelet count \\\u003C100 x 10\\^9\u002FL (\\\u003C100,000\u002Fmm\\^3)\n    5. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal (ULN)\n    6. Estimated glomerular filtration rate of less than 60 mL\u002Fmin\n13. Any arrhythmia on baseline\u002Fscreening ECG.\n14. Females of childbearing potential not willing to use contraceptive methods which, in the opinion of the investigator, are effective and adequate while on the study. Female subjects who are not of childbearing potential must meet at least one of the following criteria: (a) Have undergone a documented hysterectomy and\u002For bilateral oophorectomy; or (b) Achieved postmenopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause.\n15. Been diagnosed with G6PD deficiency.\n16. Subjects who are taking TCM supplements regularly (daily) and not willing to stop intake.","21 Years","70 Years",{"count":118,"type":22},132,[26,120],"PHASE3","Rheumatoid Arthritis (RA) is a chronic disease characterised by symmetric, polyarticular pain and swelling, involving small joints of the hands and feet. RA can lead to irreversible joint damage without treatment, causing disability and impacting daily activities and work productivity. Some patients turn to Chinese Herbal Medication (CHM) for treatment. Since there is currently no well designed randomised controlled trial to support the 'real-world' use of Si Miao Xiao Bi Tang with anti-rheumatic drugs, such as methotrexate, the investigators are conducting a 12-week, randomised double-blinded placebo-controlled trial to determine the efficacy, safety and cost effectiveness of a modified Si Miao Xiao Bi Tang, a type of CHM, in the treatment of patients with active RA.",[30],[70,124,125,126],"Chinese Herbal Medicine","Traditional Chinese Medicine","Si Miao Xiao Bi","2026-08-14",{"date":129,"type":43},"2026-08-17",{"date":131,"type":43},"2026-06-01",{"date":133,"type":22},"2030-06-30",{"name":135,"class":83},"Singapore General Hospital",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100650912","development-and-evaluation-of-the-effectiveness-of-the-smart-hand-protocol-for-hand-rehabilitation-in-patients-with-rheumatoid-arthritis-100650912","NCT07754552","Development and Evaluation of the Effectiveness of the SMART-HAND Protocol for Hand Rehabilitation in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Participants will be 18 years of age or older.\n* Participants will have a diagnosis of rheumatoid arthritis for at least five years.\n* Participants will be referred by a rheumatologist.\n* Participants will have been on a stable medication regimen for the past three months.\n* Participants will have no history of diabetes mellitus.\n* Participants will have no other conditions affecting sensory function.\n* Participants will provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Individuals who have undergone hand surgery within the past six months.\n* Individuals with a history of upper extremity fracture within the past six months.\n* Individuals with other musculoskeletal pain conditions involving the muscles and\u002For joints.\n* Individuals diagnosed with a neurological disease that may affect sensory or motor function.\n* Individuals who are unable to fully cooperate with the assessment procedures.\n* Individuals who have received corticosteroid treatment within the past month.\n* Individuals diagnosed with another rheumatic disease.\n* Pregnant women.\n* Individuals who are illiterate.\n\nWithdrawal\u002FDiscontinuation Criteria\n\n* Participants who miss more than 10% of the intervention sessions will be excluded from the study.\n* Participants who change their medication dosage or medication class during the study period will be excluded from the study.\n* Participants will have the right to withdraw from the study at any time and for any reason.",{"count":118,"type":22},[144],"NA","Rheumatoid arthritis (RA) frequently affects the hand and wrist, resulting in pain, reduced joint stability, impaired proprioception, muscle weakness, and limitations in daily activities. Although conventional rehabilitation primarily focuses on range of motion and strengthening exercises, sensorimotor impairments such as proprioceptive deficits are often underaddressed. The SMART-HAND (Sensory, Massage, Approximation, ROM, Training = Strengthening + Perturbation) protocol was developed as a structured, mechanism-based rehabilitation program to improve proprioception, joint stability, motor control, and hand function. This randomized controlled trial aims to evaluate the effectiveness of the SMART-HAND protocol in individuals with RA by comparing its effects on hand function, proprioception, pain, dexterity, muscle strength, and functional performance with conventional rehabilitation and a control group.",[70,98,147],"Rheumatoid Arthritis (RA) Prevention",[70,149,150,151,152,153,154],"Hand Rehabilitation","Hand Function","Proprioception","Neuromuscular Control","Grip Strength","Joint Stability","2026-08-13",{"date":127,"type":43},{"date":103,"type":22},{"date":159,"type":22},"2027-12-30",{"name":161,"class":83},"Istanbul University - Cerrahpasa",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":84},"100652215","integrative-ai-based-multiomic-and-neurophysiological-profiling-of-chronic-pain-in-rheumatoid-arthritis-100652215","NCT07769619","Integrative AI-Based Multiomic and Neurophysiological Profiling of Chronic Pain in Rheumatoid Arthritis","RA-PAIN-AI","Inclusion Criteria - Study Group (Active RA)\n\n* Age ≥18 years.\n* Confirmed diagnosis of rheumatoid arthritis according to applicable classification criteria.\n* Active phase of the disease requiring initiation of biological therapy.\n* Qualification for treatment under the national drug program B.33: \"Treatment of rheumatoid arthritis and juvenile idiopathic arthritis with aggressive course (ICD-10: M05, M06, M08)\".\n* Ability to provide written informed consent.\n* Willingness to participate in clinical assessments, EEG, biological sample collection, and questionnaire-based evaluation.\n\nExclusion Criteria - Study Group\n\n* Contraindications to biological therapy as defined by the Polish Society of Rheumatology recommendations and the National Health Fund (NFZ) requirements under the B.33 drug program.\n* Inability to provide informed consent.\n* Any condition that, in the opinion of the investigator, may interfere with study participation or data interpretation.\n\nInclusion Criteria - Control Group (RA in Remission)\n\n* Age ≥18 years\n* Confirmed diagnosis of rheumatoid arthritis.\n* Ongoing biological therapy with sustained remission for at least 1.5 years and good tolerance of the treatment.\n* No current chronic pain reported in the clinical interview.\n* Ability to provide written informed consent.\n* Willingness to participate in study procedures, including biological sampling, EEG and questionnaire assessments.",{"count":170,"type":22},100,"Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease in which pain remains the most prominent and burdensome symptom from the patient's perspective. Although the introduction of biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) has significantly improved the control of inflammatory activity, an estimated 20-30% of patients continues to experience persistent moderate-to-severe pain despite achieving clinical remission. This discordance between objective inflammatory markers and subjective pain perception reflects an important unmet clinical need and suggests that chronic pain in RA may become partially or fully independent of peripheral inflammation, driven instead by central sensitization and nociplastic mechanisms. The RA-PAIN-AI study is a prospective, observational, case-control study integrating clinical assessment, patient-reported outcome measures, neurophysiological evaluation, and multiomic profiling, analyzed using artificial intelligence (AI)-based methods. Two groups of adult patients with RA are enrolled: a study group of patients with active disease qualifying for biological therapy under the Polish national drug program B.33, and a control group of patients in sustained clinical remission (at least 1.5 years) under biological therapy, without clinically significant chronic pain. All participants undergo clinical assessment, standardized questionnaires, peripheral blood collection at the baseline (Visit 1) and follow-up (Visit 2) visits. Electroencephalography (EEG) is offered as an optional procedure, at the discretion of the investigator. Biological samples are analyzed using advanced multiomic technologies, including whole genome sequencing (genomics), mRNA expression profiling (transcriptomics), and measurement of circulating proteins (secretomics). All clinical, biological, and neurophysiological data are then integrated using AI methods, including dimensionality reduction, clustering, and supervised machine learning, to identify distinct pain-related patient subtypes (endotypes). The primary objective of the study is to identify and characterize clinical, neurophysiological, and multiomic signatures associated with chronic pain in RA. Expected outcomes include identification of biomarkers predictive of chronic pain persistence despite effective anti-inflammatory treatment, improved differentiation between inflammation-driven pain and pain mediated by central nervous system changes, and support for the development of more personalized, mechanism-based treatment strategies in rheumatology. The study is non-interventional: no experimental therapeutic interventions are administered, and all participants continue to receive standard clinical care. All biological analyses are performed ex vivo.",[98,173],"Chronic Pain",[175,176,177,178,179,180,181,182,183,184],"multiomics","pain endotypes","precision medicine","biomarkers","artificial intelligence","electroencephalography","nociplastic pain","secretomics","transcriptomics","ACPA","2026-08-12",{"date":187,"type":43},"2026-08-18",{"date":131,"type":43},{"date":190,"type":22},"2029-06-06",{"name":192,"class":83},"4th Military Clinical Hospital with Polyclinic, Poland",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":200,"maxAge":60,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100651377","self-care-education-for-joint-stiffness-and-functional-ability-in-rheumatoid-arthritis-100651377","NCT07761767","Self-Care Education for Joint Stiffness and Functional Ability in Rheumatoid Arthritis","Effectiveness of a Self-Care Educational Program on Joint Stiffness and Functional Ability in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* The criteria for selection were: patients\" age ranged between 20-65 years old; did not have any auditory, visual or psychological problems. Patients who are able to communicate and participate in the educational program.\n\nPatients who agree to participate in the study.\n\nExclusion Criteria:\n\n* Patients with severe cognitive or communication impairment. Patients with other severe musculoskeletal conditions that may affect functional ability.\n\nPatients who have participated in a similar self-care educational program recently.","20 Years",{"count":202,"type":22},110,[144],"Rheumatoid arthritis is a chronic inflammatory autoimmune disease that may cause joint stiffness, pain, reduced mobility, and impaired functional ability. Self-care education may help patients improve their knowledge and practices related to disease management, joint protection, physical activity, exercise, energy conservation, and symptom management.\n\nThis study aims to evaluate the effectiveness of a self-care educational program on joint stiffness and functional ability among patients with rheumatoid arthritis. Participants will be assigned to either a study group or a control group. The study group will receive the self-care educational program in addition to routine care, while the control group will receive routine care only. Joint stiffness and functional ability will be assessed before and after implementation of the educational program.",[30],[70,207,208,209],"Self-Care","Joint Stiffness","Functional Ability",{"date":155,"type":43},{"date":78,"type":22},{"date":213,"type":22},"2027-04-01",{"name":107,"class":83},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100611854","phase-1-a-study-of-f8il10-intra-articular-treatment-in-rheumatoid-arthritis-100611854","NCT07245992","A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis","A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis","DekaJoint","Inclusion Criteria:\n\n1. Patients aged ≥18 and ≤80 years.\n2. Diagnosis of RA according to ACR\u002FEULAR classification criteria (2010) with a disease duration exceeding 6 months.\n3. Presence of arthritis flare(s) suitable for IA injection in a knee, ankle, shoulder, wrist or elbow, despite treatment with stable doses (for at least 3 months) of DMARDs (conventional, biologic, and targeted synthetic) background therapy.\n4. No or stable regimens of NSAIDs and\u002For oral corticosteroid (≤ 10 mg\u002Fday; prednisone equivalent) for a period ≥2 weeks prior to screening.\n5. All acute toxic effects of any prior therapy must have resolved or returned to classification \"mild\" (grade 1) according to CTCAE v.5.0.\n6. Sufficient hematologic, liver and renal function defined as follows:\n\n   * Absolute neutrophil count (ANC) ≥1.5 x 109\u002FL, platelets ≥100 x109\u002FL, haemoglobin (Hb) ≥10.0 g\u002FdL.\n   * Alkaline Phosphatase (AP), Alanine Aminotransferase (ALT) and or Aspartate Aminotransferase (AST) ≤3 x Upper Limit of Normal Range (ULN), and total bilirubin ≤2.0 mg\u002Fdl (34.2 μmol\u002FL).\n   * Creatinine ≤1.5 ULN or 24 h creatinine clearance ≥50 mL\u002Fmin.\n7. Documented negative TB test (e.g. Quantiferon or equivalent).\n8. Documented negative test for HIV-HBV-HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and\u002For anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no ongoing infection are eligible.\n9. Sexually active male or female patients of childbearing potential are eligible providing that:\n\n   * Women of childbearing potential (WOCBP) have a negative pregnancy test performed within 4 weeks prior to treatment start.\n   * WOCBP agree to use, from the screening to 6 months following the last study drug administration, effective method of birth control as applicable per local law that both results in a Pearl index \\\u003C1 and considered highly effective as defined by the \"Recommendations for contraception and pregnancy testing in clinical trials\" issued by the \"Clinical Trial Facilitation Group\" (e.g. combined estrogen and progestogen containing hormonal contraception, progestogen-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, vasectomized partner, total sexual abstinence or bilateral tubal occlusion).\n   * Males agree to use two acceptable methods of contraception (e.g. condom with spermicidal gel) from the screening to 6 months following the last study drug administration. Females of childbearing potential that are partners of male study participants must observe the same birth control indications that apply to female participants.\n10. Signed and dated Ethics Committee-approved informed consent form indicating that the patient, or patient's legally acceptable representative, has been informed of all pertinent aspects of the study.\n11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n1. Presence of additional RA flares or RA-related symptoms that, in the investigator's judgment, are likely to require local treatment during the study (defined as intra-articular or peri-articular injections\u002Fprocedures intended to treat RA; e.g., joint, tendon-sheath, or bursal corticosteroid injections; hyaluronic acid; biologic\u002FPRP injections; or radio synovectomy).\\_\n2. Presence of active infections or another severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.\n3. Pregnancy, lactation or unwillingness to use adequate contraceptive methods.\n4. Diagnosis of any other inflammatory arthritis or active autoimmune diseases other than RA.\n5. Any therapy for RA apart from the allowed background therapy (i.e., stable doses of DMARDs, corticosteroids, and\u002For NSAIDs) within 4 weeks prior to the first IMP dosing.\n6. Received intra-articular administration of corticosteroids\u002FDMARDs within 4 weeks or 5 half-lives prior to the first IMP dosing, whichever is longer.\n7. History or currently active primary or secondary immunodeficiency.\n8. Concurrent malignancy or history of malignancy (except in situ melanoma and low-risk non melanoma skin cancer) from which the patient has been disease-free for less than 2 years.\n9. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.\n10. Treatment with warfarin or other coumarin derivatives.\n11. Clinically significant cardiac arrhythmias or requiring permanent medication.\n12. Abnormalities in baseline ECG analysis that are considered as clinically significant by the investigator; subjects with current or a history of QT\u002FQTc prolongation.\n13. Uncontrolled hypertension, despite optimal treatment.\n14. Known arterial aneurism at high risk of rupture.\n15. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche Fontaine classification).\n16. Severe diabetic retinopathy.\n17. Major trauma including surgery within 4 weeks prior to administration of study treatment.\n18. Known history of allergy\u002Fhypersensitivity or other intolerance to any component of F8IL10 (including excipients) or to other drugs based on human proteins\u002Fpeptides\u002Fantibodies.\n19. Treatment with any investigational agent within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.\n20. Immunization with a live\u002Fattenuated vaccine within 4 weeks prior to baseline or plan to receive vaccines during the study.\n21. Non-RA related chronic pain disorders.\n22. Patients requiring stable doses of corticosteroids \\>10 mg\u002Fday (prednisone equivalent). Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.\n23. History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.\n24. Any condition that in the opinion of the investigator could hamper compliance with the study protocol.","80 Years",{"count":225,"type":22},42,[25],"The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.",[30],[70],"2026-08-10",{"date":232,"type":43},"2026-08-11",{"date":234,"type":43},"2026-03-04",{"date":236,"type":22},"2029-09-30",{"name":238,"class":50},"Philogen S.p.A.",2,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":84},"100651488","oxidative-stress-and-cardiovascular-risk-in-patients-with-rheumatoid-arthritis-100651488","NCT07760662","Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis","Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis","PIFIISC23\u002F07","Inclusion Criteria:\n\n* Men or women who are not pregnant or breastfeeding.\n* Age 18 years or older and younger than 70 years.\n* Treatment with any disease-modifying antirheumatic drug, including biologic therapies.\n* For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion.\n* Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care.\n* History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease.\n* Estimated glomerular filtration rate below 60 mL\u002Fmin\u002F1.73 m² or active renal disease.\n* Pregnancy or breastfeeding.\n* Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile.\n* Body weight greater than 150 kg.\n* History of alcoholism, drug abuse, or substance misuse within six months before the screening visit.\n* Statin use will not be an exclusion criterion.",{"count":249,"type":22},200,"The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis.\n\nThis cross-sectional study will include patients with RA. The primary objective is to evaluate the association between selected oxidative stress biomarkers-serum malondialdehyde levels, superoxide dismutase, and glutathione peroxidase-and the presence of subclinical atherosclerosis and carotid arterial stiffness in patients with RA. We will subsequently assess whether these molecules are related to cardiovascular disease determinants, including inflammatory dyslipidemia, insulin resistance, and beta-cell dysfunction, which may occur in this condition. This study will further explore the relationship between oxidative stress and cardiovascular disease in RA.",[98,252,253],"Oxidative Stress","Cardiovascular (CV) Risk",[255,256],"Rheumatoid arthritis","Oxidative stress","2026-08-07",{"date":185,"type":43},{"date":260,"type":43},"2024-01-01",{"date":262,"type":22},"2026-12",{"name":264,"class":83},"University of La Laguna",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":239},"100636320","phase-1-a-first-in-human-study-of-kt502-in-adult-participants-with-rheumatoid-arthritis-ra-100636320","NCT07564154","A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)","A Phase 1, Open-Label, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KT502 by Subcutaneous Administration in Adult Participants With Rheumatoid Arthritis","Inclusion:\n\n1. 18 to 75 years old\n2. Diagnosis of adult-onset RA for at least 6 months\n3. Moderately to severely active RA\n4. Inadequate treatment response as defined in the protocol\n5. RF + or ACPA+\n6. Stable use of traditional DMARDs is permitted\n7. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n\nExclusion:\n\n1. Functional class IV as defined by the ACR Classification of Functional Status in RA\n2. Presence of any concomitant autoimmune disease other than RA\n3. Active infection, history of serious recurrent or chronic infection\n4. History of progressive multifocal leukoencephalopathy\n5. Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years.\n6. History of or planned organ transplant and\u002For autologous or allogeneic hematopoietic stem cell transplantation\n7. Receipt of live vaccine within 4 weeks\n8. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study\n9. Women who are pregnant or breastfeeding\n10. Significant or uncontrolled medical disease that would preclude participant participation","75 Years",{"count":274,"type":22},27,[25],"This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.",[30],[30,279,280],"T-Cell Engagers (TCEs)","B-Cell Depletion",{"date":232,"type":43},{"date":283,"type":43},"2026-07-13",{"date":285,"type":22},"2028-07",{"name":287,"class":50},"Kali Therapeutics, Inc.",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":116,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":84},"100650583","phase-2-tll-018-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-with-inadequate-response-or-intolerance-to-csdmards-100650583","NCT07748728","TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs","A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs","Inclusion Criteria:\n\n* 1 Aged 18 to 70 years inclusive, any sex; body mass index \\[BMI = weight (kg)\u002Fheight² (m²)\\] ≤ 35 kg\u002Fm².\n\n  2 \"Meets the 2010 American College of Rheumatology\u002FEuropean Alliance of Associations for Rheumatology (ACR\u002FEULAR) classification criteria for active rheumatoid arthritis (RA), with a disease duration of at least 3 months at the screening visit： Has received conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for ≥ 3 months prior to screening, with a stable dose for at least 4 weeks before randomization； Active rheumatoid arthritis meeting all of the following criteria: ≥6 swollen joints (SJC, 66-joint count) and ≥6 tender joints (TJC, 68-joint count) at screening and baseline visits. Joints that have undergone major surgery or received intra-articular injection within 4 weeks before randomization will be excluded from SJC and TJC counts. High-sensitivity C-reactive protein (hsCRP) \\> upper limit of normal (ULN) or ≥5 mg\u002FL at baseline (CRP testing is acceptable; hsCRP is preferred).\" 3 Functional Class I, II, or III according to the 1991 American College of Rheumatology (ACR) rheumatoid arthritis functional classification criteria.\n\n  4 \"Organ function must satisfy the following laboratory criteria: Bone marrow: hemoglobin ≥90 g\u002FL; platelets ≥100 ×10⁹\u002FL; absolute neutrophil count ≥1.5 ×10⁹\u002FL; lymphocyte count ≥0.8 ×10⁹\u002FL; white blood cell count ≥2.5 ×10⁹\u002FL.\n\nHepatic function: total bilirubin ≤1.5 × ULN; aspartate aminotransferase (AST) OR alanine aminotransferase (ALT) ≤1.5 × ULN.\n\nRenal function: serum creatinine \\\u003C1.2 × ULN. Urinalysis: urine protein ≤1+. If urine protein \\>1+, a 24-hour urine protein collection is required, with total urinary protein ≤1 g.\" 5 Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding. A pregnancy test (e.g., β-HCG assay) must be performed prior to study entry (last menstrual period will be documented). All participants and their partners must agree to use effective contraception (as judged by the Investigator) from the first dose of investigational product until at least 90 days after the last dose (see Appendix 12). Participants must have no plans to donate sperm or ova from screening through at least 6 months after the last study drug administration.\n\n6 The participant understands the informed consent form, voluntarily agrees to participate in the study, and provides written informed consent. Informed consent must be obtained prior to performance of any study-related procedures.\n\nExclusion Criteria:\n\n* 1 Evidence or diagnosis of other rheumatic diseases prior to screening (secondary Sjögren's syndrome excluded), including systemic lupus erythematosus, psoriatic arthritis, mixed connective tissue disease, primary Sjögren's syndrome, dermatomyositis, polymyositis, systemic sclerosis, and ankylosing spondylitis.\n\n  2 Presence of active fibromyalgia that, in the Investigator's judgment, may interfere with the evaluation of rheumatoid arthritis disease activity.\n\n  3 Prior diagnosis of other systemic inflammatory diseases, including but not limited to juvenile chronic arthritis, inflammatory bowel disease, active vasculitis (excluding venous rheumatoid nodules), spondyloarthropathy, and psoriatic arthritis.\n\n  4 Diagnosis of Felty's syndrome (rheumatoid arthritis with splenomegaly). 5 Presence of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, or cerebral diseases that, in the Investigator's opinion, would place the participant at unacceptable risk.\n\n  6 A history of lymphoproliferative disorders (including but not limited to EBV-associated lymphoproliferative diseases, lymphoma, and leukemia), or presence of any current signs or symptoms suggestive of active lymphoproliferative disease.\n\n  7 A previous history of severe hematological diseases such as aplastic anemia and myelodysplastic syndrome, or any disease condition that may cause hemolysis or erythrocyte instability, including malaria and hemolytic anemia.\n\n  8 Current or previous history of thrombocytopenia, coagulation disorders, or platelet function disorders.\n\n  9 History of cardiovascular or cerebrovascular events or surgeries within 12 months prior to screening, including but not limited to myocardial infarction, unstable angina, acute coronary syndrome, cerebral hemorrhage, cerebral infarction, coronary stent implantation, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting.\n\n  10 History of thromboembolic events within 12 months prior to screening (e.g., pulmonary thromboembolism, deep vein thrombosis, mesenteric arterial embolism), or presence of current high thromboembolic risk factors, such as immobilization within 12 weeks before screening, congenital or hereditary thrombophilia, or antiphospholipid antibody syndrome.\n\n  11 History of gastrointestinal perforation prior to screening (perforation caused by appendicitis or trauma is excluded).",{"count":296,"type":22},90,[26],"This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).",[30],[301,302,303,304,305,306],"TLL-018 tablet","Arthritis, Rheumatoid","Janus Kinase Inhibitors","Antirheumatic Agents","Drug Resistance","Treatment Failure","2026-08-05",{"date":309,"type":43},"2026-08-06",{"date":127,"type":22},{"date":312,"type":22},"2027-12-31",{"name":314,"class":50},"Hangzhou Highlightll Pharmaceutical Co., Ltd",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":340},"100568924","phase-4-jak-inhibitor-dose-tapering-strategy-study-100568924","NCT06687551","JAK Inhibitor Dose TAPering Strategy Study","JAK Inhibitor Dose TAPering Strategy Study in Low Disease Activity Rheumatoid Arthritis Patients","JAK-TAP","The inclusion criteria will be\n\n1. Aged ≥ 18 years at baseline.\n2. Rheumatoid arthritis defined by the ACR\u002FEULAR criteria.\n3. Treated with a JAK inhibitor, full dose for at least 6 months.\n4. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.\n5. Being in LDA (CDAI≤10) for at least 6 months.\n6. With a CRP level below the laboratory standard within the month before the inclusion visit.\n7. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study\n\nThe non-inclusion criteria will be:\n\n1. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease).\n2. Patient with a history of JAK-inhibitor dose reduction\u002Fspacing before enrollment in the study with the JAK-inhibitor currently being taken.\n3. Evidence of flare-up within the last 6 months prior to the inclusion.\n4. Patient who received glucocorticoids \\> 5mg\u002Fday in the 3 months prior the inclusion because of the disease activity of the RA.\n5. Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity.\n6. Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib.\n7. Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12\u002F23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways).\n8. Patient taking immunotherapy for neoplasia.\n9. Surgery scheduled in the next 12 months.\n10. Fibromyalgia according to the physician's opinion.\n11. Anticipated poor compliance with the strategy.\n12. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation.\n13. Alcohol and\u002For drug misuse as determined by the investigator.\n14. Pregnancy or breastfeeding.\n15. Non-affiliation to the French Social Security System.\n16. Patient unwilling to sign the informed consent form.\n17. Patient under legal protection.",{"count":324,"type":22},308,[326],"PHASE4","This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.\n\nParticipants will:\n\n* Either take\n\n  1. JAK inhibitor dose-tapering strategy.\n  2. JAK inhibitor continuous therapy strategy.\n* Visit the clinic once every 3 months for checkups and tests\n* Keep a diary of their treatment intake and symptoms",[98],[330,331,255],"JAK-inhibitor","dose reduction","2026-08-04",{"date":257,"type":43},{"date":335,"type":43},"2025-06-06",{"date":337,"type":22},"2029-04-01",{"name":339,"class":83},"University Hospital, Toulouse",24,{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":116,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":84},"100650256","phase-2-clinical-study-comparing-diosmin-vs-rebamipide-as-adjuvant-therapies-vs-conventional-therapy-in-patients-with-rheumatoid-arthritis-100650256","NCT07745426","Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR). i.e.,28 joints disease activity score (DAS-28) \\>2.6.\n* Both sexes.\n* Age ranges between 18 and 70 years old.\n* Patients receiving conventional DMARDs\n\nExclusion Criteria:\n\n* Pregnant and lactating females.\n* Patients receiving biological DMARDs or targeted synthetic DMARDs.\n* Patients with renal and hepatic dysfunction.\n* Patients with other inflammatory\u002Fautoimmune diseases, active infection, or malignancies.\n* Patients with bleeding disorders, receiving warfarin or other anticoagulants.\n* Patients receiving antioxidants.\n* Patients with hypersensitivity to study medications.",{"count":348,"type":22},66,[26],"This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups:\n\n\\- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months.\n\n\\- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.\n\n\\- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.",[30],[353,354,355],"rheumatoid arthritis","diosmin","rebamipide","2026-07-29",{"date":332,"type":43},{"date":359,"type":22},"2026-08-01",{"date":361,"type":22},"2027-08-01",{"name":363,"class":83},"Tanta University",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":382,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":406},"100592260","phase-2-allonk-an-allogeneic-non-genetically-modified-cord-blood-derived-nk-cell-therapy-in-combination-with-rituximab-studied-in-relapsing-forms-of-b-cell-dependent-rheumatologic-diseases-100592260","NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.","An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases","For Subjects with Refractory Rheumatoid Arthritis (RA):\n\n* Documented diagnosis of RA, meeting the 2010 ACR\u002FEULAR classification criteria.\n* Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.\n* High-sensitivity C-reactive protein (hs-CRP) \\> 3 mg\u002FL or Erythrocyte Sedimentation Rate (ESR) \\> 28 mm\u002Fhr.\n* Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.\n* Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.\n\nFor subjects with Sjögren's Disease (SjD)\n\n* Prior diagnosis of Primary SjD as per 2016 ACR\u002FEULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.\n* Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) \\> 6.\n* Salivary Flow Rate \\> 0.1 mL\u002Fmin on stimulation.\n\nFor subjects with Idiopathic Inflammatory Myopathies (IIMs)\n\n* Presence of a positive autoantibody (ANA \\>1:80 or RNP or SSA\u002FSSB or other myositis specific autoantibodies.\n* Refractory IIM as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.\n* Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.\n\nFor Subjects with Systemic Sclerosis (SSc)\n\n* Diagnosis of SSc in accordance with the ACR\u002FEULAR 2013 classification.\n* Modified Rodnan skin score (mRSS) \\> 10.\n* Initial confirmatory diagnosis within 8 years of screening.\n* Refractory SSc as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.",{"count":296,"type":22},[26],"A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.",[375,376,31,98,377,378,379,380,381],"Refractory Rheumatoid Arthritis (RA)","Idiopathic Inflammatory Myopathies (IIMs)","IIM","Myositis","Scleroderma","Sjogren Syndrome","Sjogrens Disease",[383,384,385,386,387,388,389,390,391,392,393,394,395,396,397],"Refractory Rheumatoid Arthritis","AlloNK","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","Sjögren's Disease","Refractory RA","Cell Therapy","Allogeneic NK Cells","Allogeneic Cell Therapy","non-genetically modified","rituximab","cord blood cells","ADCC enhancement","outpatient","community",{"date":399,"type":43},"2026-07-31",{"date":401,"type":43},"2025-07-09",{"date":403,"type":22},"2029-01",{"name":405,"class":50},"Artiva Biotherapeutics, Inc.",52,{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":84},"100649165","phase-2-the-effect-of-nicorandil-on-rheumatoid-arthritis-patients-100649165","NCT07730723","The Effect of Nicorandil on Rheumatoid Arthritis Patients","The Effect of Nicorandil on Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n* Adult (≥18 years).\n* Confirmed diagnosis with RA according to ACR\u002FEULAR 2010 criteria.\n* Moderate to severe disease activity (DAS-28 ˃ 3.2).\n* Stable on conventional treatment for at least 3 months.\n* Adequate kidney and liver function.\n\nExclusion Criteria:\n\n* Other autoimmune diseases\n* Poor patient compliance\n* Malignancy or history of malignancy\n* Pregnancy or lactation.\n* Patients receiving bDMARDs or tsDMARDs.\n* Hypersensitivity to nicorandil.\n* Left ventricular heart failure or severe hypotension (SBP ˂100 mmHg).\n* History of cardiogenic shock.\n* History or active gastric ulcer.\n* Use of drugs contraindicated with nicorandil (e.g., sildenafil, tadalafil, vardenafil, tricyclic antidepressants, or guanyl cyclase).",{"count":94,"type":22},[26,120],"The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil. The main questions it aims to answer are:\n\n* Could nicorandil improve disease severity and symptoms of rheumatoid arthritis?\n* Does nicorandil lower the number of times participants need to use pain relieve medications?\n* Does the nicorandil improve participants functionality and ability to carry out daily activity?\n* Does nicorandil correct disease-associated damage and inflammation?\n* What side effects do participants have when taking nicorandil? Researchers will compare nicorandil to a placebo (a look-alike substance that contains no drug) to see if nicorandil works to decrease symptoms and severity of rheumatoid arthritis.\n\nParticipants will:\n\n* Take nicorandil or a placebo two times daily for 3 months\n* Visit the clinic once every month for checkups\n* Keep a diary of their symptoms and the number of times they use a pain reliever",[30],[30,419,420,421,422,423,424,425],"Nicorandil","Inflammation","DAS-28","Disease activity","Autoimmune disease","HAQ-DI","Quality of life","2026-07-23",{"date":428,"type":43},"2026-07-28",{"date":430,"type":22},"2026-08",{"date":432,"type":22},"2027-07",{"name":434,"class":83},"Ain Shams University",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":442,"maxAge":272,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":84},"100649075","phase-1-baff-car-t-cells-lmy-922-for-treatment-of-refractory-autoimmune-disease-100649075","NCT07729995","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease","A Phase 1 Study of Allogeneic (γ\u002Fδ) BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease","Inclusion Criteria:\n\nParticipants must meet all the following inclusion criteria to be eligible for enrollment:\n\n1. Male or female 16-75 years of age, inclusive.\n2. For participants with:\n\n   a. Rheumatoid Arthritis:\n\n   i. Meets criteria for seropositive, adult-onset RA as defined by the 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria, or seropositive (rheumatoid factor positive) polyarticular juvenile arthritis as defined by the International League of Associations for Rheumatology (ILAR) classification criteria for at least 3 months prior to screening\n\n   ii. Disease Activity Score DAS28-ESR\\>3.2 at screening.\n\n   iii. At least one swollen joint with Power Doppler activity of at least grade 1 or B-mode activity of at least grade 2 at screening.\n\n   iv. Inadequate response to at least one csDMARD and at least two tsDMARD\u002FbDMARDs with two different mechanisms of action.\n\n   v. Rheumatoid factor or ACPA positivity (cut off 20 mU\u002Fml) at screening.\n\n   b. Systemic Lupus Erythematosus:\n\n   i. Meets European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) Classification Criteria for Systemic Lupus Erythematosus prior to screening\n\n   ii. Participant must be positive for at least one of the following at screening: Anti-dsDNA (above the upper limit of normal \\[ULN\\]); or anti-Sm (above the ULN); or anti-chromatin\n\n   iii. An inadequate response to at least two immunomodulatory agents (cyclophosphamide, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil) and one biologic agent (e.g., belimumab, anifrolumab)\n\n   iv. Diagnosed with active SLE based on at least one of the following: 1. Active non-renal SLE with SLEDAI score ≥6 at screening; 2. Biopsy proven lupus nephritis (LN) with a urine protein creatinine ratio of ≥1 mg\u002Fmg on a first morning void. A biopsy must be performed in the 6 months prior to the screening showing active LN class III or IV, with or without class V, in accordance with the 2018 International Society of Nephrology\u002FRenal Pathology Society classification.\n\n   c. Dermatomyositis:\n\n   i. Meets 2017 EULAR\u002FACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies for definite or probable diagnosis of DM or juvenile DM at least 6 months before screening.\n\n   ii. Positivity for at least one myositis-specific antibody (aminoacyl tRNA synthetases, Mi2, MDA5, SAE, SRP, ARS, HMGCR, MJ, TIF1gamma)\n\n   iii. Active DM as defined by at least one of the following: Active skin disease as defined by a CDASI-A score of at least 14, or active muscle disease as defined as Manual Muscle Testing (MMT-8) score \\\u003C142\u002F150 and creatine kinase, aldolase, LDH, AST, or ALT ≥2×ULN (if deemed due to muscle inflammation by investigator) and MRI evidence of active myositis within last 3 months.\n\n   iv. Failure of at least 2 standard-of-care therapies, including csDMARDs + corticosteroids and bDMARD or IVIG\n\n   v. Inadequate response to intravenous immunoglobulin (IVIG) and at least two immunomodulator agents: cyclophosphamide, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil and one biologic agent (e.g., rituximab, belimumab).\n\n   d. Systemic Sclerosis:\n\n   i. Per 2013 ACR\u002FEULAR classification criteria and all of the following: 1. Disease duration of ≤ 3 years (time from the first non-Raynaud phenomenon manifestation); 2. mRSS \\> 10 at screening with early disease or rapid progression, or mRSS ≥ 15 with disease duration ≥ 18 month.; 3. Positivity for at least one SSc-specific parameter (Scl70, RNA polymerase, Th\u002FTo, RP11\u002F12, U3RNP autoantibodies); 4. Failure of treatment with at least 2 standard-of-care therapies, including ≥2 csDMARDs (including mycophenolate or cyclophosphamide) and ≥1 bDMARD (including rituximab); 5. Diffuse SSc with or without interstitial lung disease (ILD)\n3. Stable doses of corticosteroids for at least 4 weeks and other immunosuppressives for 8 weeks.\n4. Adequate organ function as defined by each of the following:\n\n   1. Creatinine clearance more than or equal to 45 ml\u002Fmin calculated per the 2021 CKD-EPI Creatinine Equation\n   2. Participants must have adequate cardiac function as defined as left ventricular ejection fraction ≥ 45% on the most recent echocardiogram and no clinically significant arrhythmias, pericardial effusion, valvular, or ischemic heart disease.\n   3. Adequate pulmonary function with pulse oximetry ≥92% on room air.\n   4. Total Bilirubin \\\u003C 1.5× the institutional upper limit of normal (except in participants with Gilbert's syndrome).\n   5. ALT (SGPT) and AST (SGOT) \\\u003C 1.5× the institutional upper limit of normal (except for participants with active myositis).\n   6. Hemoglobin ≥ 8.5 g\u002FdL, and no red blood cell transfusion within 60 days before the laboratory test.\n   7. Platelets ≥ 100,000\u002FμL, no transfusion support within 7 days before the laboratory test, and no associated bleeding.\n   8. Absolute neutrophil count ≥1000.\n5. Participants (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.\n6. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \\\u003C 1% per year during the treatment period and for at least 1 year after the BAFF CAR-T cell infusion.\n\n   A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (\\\u003C 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus).\n\n   Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n7. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for at least 1 year after the BAFF CART cell infusion. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 1 year after the BAFF CAR-T cell infusion to avoid potential embryonal or fetal exposure.\n\n   The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n8. Body weight of at least 55kg for participants treated at Dose Level 3 (450 × 10\\^6 BAFF+ CAR cells) and at least 37kg for all other dose levels.\n9. Participants must be vaccinated per institutional guidelines at least four weeks prior to lymphodepletion.\n\nExclusion Criteria:\n\nThe presence of any of the following will exclude a participant from study enrollment:\n\n1. Significant disease-related complications\n\n   a. For Systemic Lupus Erythematosus participants:\n\n   i. Features of severe neuropsychiatric lupus, including seizures, psychosis, stroke, lupus cerebritis or lupus meningitis. Prior history of severe neuropsychiatric lupus with active features should be discussed with the medical monitor\n\n   ii. Active secondary hemophagocytic lymphohistiocytosis (sHLH)\u002Fmacrophage activation syndrome (MAS)\n\n   iii. History of antiphospholipid syndrome diagnosed by ACR\u002FEULAR criteria (isolated obstetric antiphospholipid syndrome is allowed) b. For Dermatomyositis participants: i. Overlap myositis\u002Fconnective tissue disease (except for overlap with Sjögren's syndrome) ii. Participants with other types of myositis or myopathies: polymyositis, paraneoplastic myositis, inclusion body myositis, metabolic or drug induced myopathy, dystrophies\n\n   c. For Systemic Sclerosis participants:\n\n   i. Anticentromere antibody seropositivity\n\n   ii. SSc mimics (eg, scleromyxedema, eosinophilic fasciitis)\n\n   iii. Pulmonary arterial hypertension (PAH) as determined by right heart catheterization or on PAH approved medications for PAH. It is acceptable to use PDFE-5 inhibitors for Raynaud's and digital ulcers\n2. Active thrombotic thrombocytopenic purpura (TTP)\u002Fmicrothrombotic vasculopathy (TMA)\n3. Current or prior malignancy, unless the malignancy was treated with curative intent and the participant has no known active malignant disease present for ≥ 5 years prior to enrollment.\n4. Symptomatic congestive heart failure.\n5. Renal failure requiring regular dialysis.\n6. Uncontrolled pulmonary disease.\n7. Ongoing infection, whether controlled or uncontrolled.\n8. Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration.\n9. Active infection requiring intravenous systemic treatment.\n10. HIV seropositivity.\n11. Pregnant or breastfeeding women are excluded from this study (breastfeeding should be discontinued), because there is an unknown, but potential risk for adverse events in fetuses and nursing infants secondary to treatment of the mother with LMY-922 and lymphodepleting chemotherapy. Women of childbearing potential must have a negative serum pregnancy test\n12. Serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive participants will be excluded.)\n13. Participants with history of clinically relevant CNS pathology such as uncontrolled epilepsy, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia, and Parkinson's disease.\n14. Participants with uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n15. Participants receiving a live vaccine within 2 weeks prior to screening.\n16. Concurrent use of high dose systemic steroids and\u002For immunosuppressive therapies.\n\n    1. Steroid dose must be able to be weaned to 0.5 mg\u002Fkg\u002Fday or equivalent prior to CAR-T cell infusion.\n    2. Immunosuppressive medications must be able to be stopped at least 5 halflives prior to CAR-T cell infusion.\n17. Treatment with rituximab or other B cell depleting agent within 6 months of planned CAR-T cell infusion, or treatment with agents such as etanercept, adalimumab, anakinra, infliximab, certolizumab pegol, belimumab, golimumab, abatacept, or tocilizumab within 4 weeks or 5 half-lives (whichever is shorter) prior to planned CAR-T cell infusion.\n18. Participants with IgG levels \\\u003C 600mg\u002FdL.","16 Years",{"count":444,"type":22},94,[25],"Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory autoimmune disease, even after relapse following other treatments. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory autoimmune disease using a BAFF CAR-T cell manufacturing process with or without lymphodepletion regimen.",[30,448,449,31],"Systemic Lupus Erthematosus (SLE)","Dermatomyositis (DM)",[451,452,453],"Systemic Scleroderma","Lupus","Lupus Nephritis","2026-07-21",{"date":428,"type":43},{"date":457,"type":22},"2026-10",{"date":459,"type":22},"2030-03",{"name":461,"class":50},"Luminary Therapeutics",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":116,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":84},"100648291","phase-4-integrated-clinical-study-of-traditional-chinese-and-western-medicine-for-refractory-rheumatoid-arthritis-100648291","NCT07721142","Integrated Clinical Study of Traditional Chinese and Western Medicine for Refractory Rheumatoid Arthritis","Integrated Clinical Study of Traditional Chinese and Western Medicine for the Treatment of Refractory Rheumatoid Arthritis Using Renowned Traditional Chinese Medicines","Inclusion Criteria\n\nSubjects must meet all of the following criteria to be enrolled in this study:\n\n1. Fully understand the purpose and requirements of the trial, voluntarily participate by signing written informed consent, and be willing and able to complete the study procedures, including medication administration and follow-up assessments;\n2. Male patients aged ≥50 years with no fertility requirements, or postmenopausal female patients, younger than 70 years;\n3. Patients diagnosed with rheumatoid arthritis (RA) according to the 1987 revised criteria of the American College of Rheumatology (ACR), or the 2010 ACR\u002FEuropean League Against Rheumatism (EULAR) classification criteria;\n4. Patients with RA of the \"Wind-Damp Bi obstruction\" pattern according to traditional Chinese medicine (TCM), defined as:\n\n   * Primary symptoms: joint pain and swelling with a wandering nature; joint pain and swelling with intermittent occurrence.\n   * Secondary symptoms: aversion to wind, or spontaneous sweating; headache; heaviness of the limbs.\n\n   Tongue and pulse: pale-red tongue with thin white coating, slippery or floating pulse.Diagnosis requires at least 2 primary symptoms, or 1 primary symptom plus 2 secondary symptoms, in combination with tongue and pulse findings.\n5. Patients with confirmed moderate to severe active RA at screening, defined as ≥6 tender joints (TJC, based on 68-joint count) and ≥6 swollen joints (SJC, based on 66-joint count), with erythrocyte sedimentation rate (ESR) \\>28 mm\u002Fh or C-reactive protein (CRP) \\>10 mg\u002FL, and DAS28-CRP \\>3.2;\n6. Prior inadequate response (DAS28-ESR \\>3.2) to at least two disease-modifying antirheumatic drug (DMARD) regimens (excluding methotrexate + JAK inhibitor + Kunxian capsule), each administered for at least 12 weeks.\n\nExclusion Criteria\n\nSubjects meeting any of the following conditions will not be eligible for enrollment:\n\n1. Suspected or confirmed allergy to the investigational drug (including excipients or drugs of the same class), or any other severe allergic disease (excluding RA itself) that, in the investigator's judgment, may compromise subject safety;\n2. Presence of inflammatory diseases other than RA, including but not limited to psoriatic arthritis, ankylosing spondylitis, or systemic lupus erythematosus;\n3. Severe, progressive, or uncontrolled diseases of the kidneys, liver, blood, gastrointestinal tract, endocrine system, lungs, heart, nervous system, psychiatric conditions, or brain; history of venous thromboembolism, diverticulitis, significantly abnormal or poorly controlled blood lipids;\n4. History of lymphoproliferative disorders, or current or past malignancy;\n5. Meeting any of the following criteria for tuberculosis screening, which require exclusion:\n\n   * History of active tuberculosis;\n   * Recent close contact with patients with active tuberculosis;\n   * Signs or symptoms of active tuberculosis based on medical history and physical examination;\n   * Chest CT scan within 3 months prior to enrollment showing evidence of active pulmonary tuberculosis;\n   * Positive interferon-gamma release assay (IGRA) within 6 weeks prior to enrollment;\n6. Presence or history of active infections, including:\n\n   * Receipt of systemic anti-infective therapy within 4 weeks prior to randomization;\n   * Pharyngalgia, nasal congestion, acute upper respiratory tract infection, or systemic acute infection within 2 weeks prior to randomization;\n   * Recurrent, chronic, or other active infections at screening that, in the investigator's judgment, may increase subject risk;\n7. History of recurrent herpes zoster, disseminated herpes zoster, or disseminated herpes simplex, or history of herpes zoster or herpes simplex within 2 months prior to randomization;\n8. Positive hepatitis B surface antigen (HBsAg) and\u002For HBV DNA \\>50 IU\u002FmL (or \\>500 copies\u002FmL) at screening; positive hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody;\n9. Receipt of, or planned receipt of, live or attenuated vaccines within 3 months prior to the first dose of study medication, during the study, or within 6 months after the last study dose;\n10. Pregnant, breastfeeding, planning pregnancy, or planning fatherhood during the study or within 6 months after the last dose; females or males with fertility requirements;\n11. Clinically significant abnormalities on 12-lead ECG at screening that may increase subject risk, in the investigator's judgment;\n12. Any other disease at screening that may interfere with study assessments;\n13. Laboratory abnormalities at screening, defined as:\n\n    1. Hemoglobin \\\u003C100.0 g\u002FL in males, or \\\u003C90.0 g\u002FL in females;\n    2. White blood cell (WBC) count \\\u003C4.0 × 10⁹\u002FL;\n    3. Neutrophil count \\\u003C1.5 × 10⁹\u002FL;\n    4. Platelet (PLT) count \\\u003C100 × 10⁹\u002FL;\n    5. Lymphocyte count \\\u003C0.5 × 10⁹\u002FL;\n    6. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), or serum creatinine (Scr) above the upper limit of normal;\n    7. Hematology, liver function, or renal function abnormalities that, in combination with medical history and\u002For additional examinations, are deemed clinically significant by the investigator;\n14. Prior use of any of the following drugs or treatments:\n\n    1. Strong opioids within 1 week prior to randomization;\n    2. Any JAK inhibitor within 2 weeks prior to randomization;\n    3. Nonsteroidal anti-inflammatory drugs (NSAIDs) at the time of randomization with dosage adjustments within 2 weeks prior;\n    4. Prednisone or equivalent corticosteroid \\>10 mg\u002Fday at randomization; or ≤10 mg\u002Fday with dosage adjustment within 4 weeks prior to randomization;\n    5. Intra-articular, intramuscular, intravenous, trigger-point, bursal, or tendon-sheath corticosteroid injections within 4 weeks prior to randomization or during the study;\n15. Concurrent participation in another drug clinical trial;\n16. Any clinically significant abnormalities in clinical or laboratory examinations, or any other reason deemed inappropriate for study participation by the investigator.",{"count":470,"type":22},300,[326],"To evaluate the efficacy and safety of Kunxian Capsule combined with Methotrexate and Tofacitinib in the treatment of difficult-to-treat rheumatoid arthritis through a multicenter, randomized, double-blind, placebo-controlled clinical trial, and to identify the therapeutic advantages of integrated Chinese and Western medicine for optimizing the clinical strategy of D2T RA.",[30],"2026-07-19",{"date":476,"type":43},"2026-07-22",{"date":478,"type":43},"2025-10-15",{"date":480,"type":22},"2028-03-15",{"name":482,"class":83},"Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":84},"100630174","clinical-cohort-construction-and-therapeutic-effect-evaluation-of-integrated-traditional-chinese-and-western-medicine-in-the-treatment-of-rheumatoid-arthritis-100630174","NCT07484243","Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Meet the RA classification criteria established by ACR in 1987 or the revised RA diagnostic criteria by ACR\u002FEULAR in 2010;\n2. D2T-RA must comply with the D2T-RA diagnostic criteria by ACR\u002FEULAR in 2020 or the China D2T-RA diagnostic criteria in 2021;\n3. RA-ILD patients require joint evaluation by rheumatologists and pulmonologists, with a clear diagnosis of ILD and exclusion of other possibilities such as pneumoconiosis, allergic alveolitis, idiopathic pulmonary fibrosis, and other connective tissue disease-related interstitial lung diseases (CTD-ILD);\n4. Traditional Chinese medicine syndrome differentiation standards refer to the \"Guidelines for Diagnosis and Treatment of Rheumatoid Arthritis\" by the China Association of Chinese Medicine, the \"Clinical Research Guidelines for New Traditional Chinese Medicine Drugs\" by the National Medical Products Administration, and the \"Diagnostic and Therapeutic Criteria for Traditional Chinese Medicine Diseases\" by the Institute of Clinical Research of the China Academy of Chinese Medical Sciences;\n5. Receive traditional Chinese medicine treatment;\n6. Age ≥18 years;\n7. Sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe, progressive, or uncontrolled diseases of the kidneys, liver, blood, gastrointestinal tract, endocrine system, lungs, heart, nervous system, mental health, or brain, or current known malignant tumors;\n2. Known clinically significant environmental exposures that may cause pulmonary fibrosis (PF), including but not limited to dust, asbestos, beryllium, radiation, amiodarone, bleomycin, etc.;\n3. Poorly controlled severe asthma or chronic obstructive pulmonary disease (COPD) with medication adjustments within 3 months prior to screening;\n4. Active infections that the investigator deems may interfere with study assessment;\n5. Any clinically or laboratory abnormalities deemed significant by the investigator or other reasons that disqualify participants from this clinical study.",{"count":490,"type":22},10000,"This is a large-scale, multicenter observational study on the treatment of rheumatoid arthritis (RA) with integrated Traditional Chinese and Western medicine.\n\nThe study plans to enroll at least 10,000 patients, including a minimum of 1,000 cases with difficult-to-treat RA (D2T RA) and 1,000 cases with RA-associated interstitial lung disease (RA-ILD). Through long-term follow-up, data will be collected on Traditional Chinese Medicine (TCM) syndrome characteristics, treatment plans, adverse drug reactions, and complications. Biological samples, including blood and urine, will also be collected.\n\nThe research will utilize multi-omics technologies such as genomics and proteomics, combined with clinical data, to deeply explore the modern scientific connotation of the \"disease-syndrome-symptom\" framework in RA. The goal is to clarify the patterns and advantages of TCM syndrome differentiation and treatment. Based on these findings, a scientific and standardized efficacy evaluation system for integrated treatment will be established, and optimized treatment strategies for D2T RA and RA-ILD will be developed.\n\nThe project is led by multiple national TCM clinical research centers and regional diagnostic and treatment centers, including the First Teaching Hospital of Tianjin University of TCM and Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine. These institutions have mature clinical research platforms, biobanks, and databases, providing a solid foundation for the successful implementation of this study.\n\nThe results of this research will provide a scientific basis for the integrated treatment of RA, promote the standardization of diagnostic and treatment protocols, and ultimately improve the overall level of RA prevention and treatment in China.",[30,493,494],"Rheumatoid Arthritis-Associated Interstitial Lung Disease","Difficult-to-Treat Rheumatoid Arthritis",{"date":454,"type":43},{"date":497,"type":43},"2025-08-22",{"date":499,"type":22},"2029-03-31",{"name":501,"class":83},"Dongyi He",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":239},"100623830","dysphagia-in-rheumatoid-arthritis-100623830","NCT07401732","Dysphagia in Rheumatoid Arthritis","Prediction of Dysphagia and Its Possible Causes in Rheumatoid Arthritis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients with Rheumatoid arthritis defined by the American College of Rheumatology\u002FEuropean League Against Rheumatism collaborative initiative (ACR\u002FEULAR) 2010 classification criteria.\n* Patients aged above 18 years old, well-orientated, and cooperative.\n\nExclusion Criteria:\n\n* concomitant thyroid dysfunction.\n* concomitant hypovitaminosis D.\n* concomitant cancer diagnosis, pregnancy.\n* jaw-related traumas, teeth, and gum diseases.\n* other rheumatologic conditions\n* other comorbidities.\n* other causes of TMJ arthritis, patients with TMJ, palatal or tongue congenital abnormalities, and patients who underwent TMJ injections in the last six months.\n* Patients with any language disorders or intellectually handicapped (as certain questions depend on the patient's ability to comprehend and express their emotions regarding their issue) and patients with anatomical anomalies impeding the functionality of flexible nasofibroscopy.\n* Any apparent causes of dysphagia other than RA.",{"count":510,"type":22},30,"The primary goal of this cross-sectional study is to assess risk factors\u002Fpredictors for dysphagia in RA.\n\nThe secondary goals include demonstrating whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with rheumatoid arthritis (RA) and whether both oropharyngeal and esophageal dysphagia are present among these patients.\n\nThe main questions it aims to answer are\n\n* What are the predictors that are associated with dysphagia via flexible fiberoptic pharyngolaryngoscopy in rheumatoid arthritis patients?\n* Whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with RA?\n* Whether both oropharyngeal and esophageal dysphagia are present in patients with RA?",[98],[514,515,516,517],"Flexible Endoscopic Evaluations of Swallowing","Temporomandibular joint","Deglutition disorders","cricoarytenoid",{"date":454,"type":43},{"date":520,"type":43},"2026-02-07",{"date":430,"type":22},{"name":363,"class":83},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":531,"sex":18,"minAge":532,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":548,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":239},"100599701","phase-4-safety-and-immunogenicity-of-the-live-attenuated-tetravalent-butantan-dengue-vaccine-in-autoimmune-rheumatic-diseases-100599701","NCT07087912","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas","BTNDV-ARD","Inclusion Criteria:\n\n* Age between 12 and 59 years\n* Male or female\n* Clinical diagnosis of an autoimmune rheumatic disease (ARD) based on internationally accepted criteria (e.g., rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren's syndrome, vasculitis)\n* Healthy control matched by age and sex\n* ARD patients with clinically stable disease for at least 3 months\n* ARD patients under low-grade immunosuppression or no immunosuppression\n* Acceptable immunosuppressive treatments include:\n\nHydroxychloroquine Sulfasalazine Prednisone ≤ 20 mg\u002Fday Methotrexate ≤ 0.4 mg\u002Fkg\u002Fweek (maximum 20 mg\u002Fweek) Leflunomide 20 mg\u002Fday Azathioprine \\\u003C 3 mg\u002Fkg\u002Fday Combination therapy with low-dose prednisone (≤ 7.5 mg\u002Fday), hydroxychloroquine, or sulfasalazine\n\n* Healthy controls with no history of autoimmune or chronic infectious diseases\n* Healthy controls not taking immunosuppressive medications Willing and able to comply with study procedures and follow-up\n* Female participants of reproductive potential with negative pregnancy test at baseline\n* Female participants of reproductive potential agreeing to use effective contraception for at least 90 days after vaccination\n\nExclusion Criteria:\n\n* Prior receipt of any dengue vaccine\n* Receipt of a live attenuated vaccine within 4 weeks prior to enrollment\n* Receipt of an inactivated vaccine within 2 weeks prior to enrollment\n* Known allergy to any component of the vaccine\n* Febrile illness (≥ 37.8°C) within 72 hours prior to vaccination\n* History of immunodeficiency syndromes\n* History of asplenia\n* History of cancer\n* History of HIV infection\n* History of primary immunodeficiencies\n* Immunosuppression due to organ transplant\n* Chronic uncontrolled comorbidities (e.g., heart failure, renal failure, hepatic insufficiency, diabetes mellitus)\n* Hospitalization or acute illness at screening\n* Receipt of blood transfusion within 3 months prior to enrollment\n* Current pregnancy or breastfeeding\n* Intention to become pregnant within 90 days post-vaccination\n* Participation in another clinical trial within 30 days prior to enrollment",true,"12 Years","59 Years",{"count":535,"type":22},477,[326],"The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune rheumatic diseases (ARDs) who are clinically stable and under low-grade or no immunosuppression, as well as in healthy volunteers matched by sex and age.\n\nThe main questions it aims to answer are:\n\nDoes the vaccine induce adequate seroconversion in patients with ARDs compared to healthy controls? What is the frequency and intensity of common adverse events after vaccination in ARDs patients? Does physical activity levels and nutritional status influence vaccine-induced immune response in patients with ARDs?\n\nResearchers will compare patients with ARDs to healthy controls to evaluate if the vaccine elicits similar immune responses and safety profiles.\n\nAll participants will:\n\n* receive a single 0.5 mL dose of the Butantan-DV vaccine via subcutaneous injection;\n* undergo blood sample collection before and after vaccination (baseline, Day 42, and Day 400) to assess antibody and cellular responses;\n* attend follow-up visits on Days 7, 14, and 42 for safety monitoring and laboratory tests;\n* report any symptoms or adverse events using a standardized diary for 42 days;\n* be followed for up to one year for long-term safety and immunogenicity assessments.\n* wear a device for 14 consecutive days to assess current and habitual physical activity levels.\n* answer three non-consecutive 24-hour dietary recalls, including at least one weekend day to assess nutritional status.\n* collect blood samples one-year after vaccination to access immunogenicity and cellular response.\n\nResearcher will also perform subgroups analysis in:\n\nA viremia subgroup (50 patients and 50 healthy controls) will provide additional samples on Days 1, 7, 14, 28, 42, and-if viremia is detected-Day 68, to evaluate post-vaccination viremia and its duration.\n\nAn immunogenicity subgroup (\\~20% of participants, n=96) will undergo cellular immune response testing via flow cytometry to evaluate T-cell responses.",[30,539,540,541,31,376,542,543,544,545,546,547],"Juvenile Idiopathic Arthritis (JIA)","Systemic Lupus Erythematosus (SLE)","Juvenile Systemic Lupus Erythematosus","Axial Spondyloarthritis","Psoriatic Arthritis (PsA)","Granulomatosis With Polyangiitis","Microscopic Polyangiitis","Antiphospholipid Syndrome","Takayasu Arteritis",[549,550,551,552,553,554,555],"Tetravalent Vaccine","Butantan-Dengue Vaccine","Autoimmune Rheumatic Diseases","Rheumatology","Pediatric Rheumatology","Infectious Disease Prevention","Vaccine","2026-07-17",{"date":558,"type":43},"2026-07-20",{"date":560,"type":43},"2026-03-16",{"date":105,"type":22},{"name":563,"class":83},"University of Sao Paulo General Hospital",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":571,"maxAge":572,"enrollmentInfo":573,"targetDuration":575,"studyType":64,"phases":4,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":588},"100617236","the-coronary-artery-calcium-and-troponins-in-rheumatoid-arthritis-cat-ra-study-100617236","NCT07315997","The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study","CAT-RA","Inclusion Criteria:\n\n* RA diagnosed by a rheumatologist\n* Age 40- 79\n* ≥1 ASCVD risk factor including prediabetes, hypertension, BMI \\>30, current or history of cigarette smoking\n\nExclusion Criteria:\n\n* Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor\n* Patients with diabetes mellitus\n* Pregnancy","35 Years","79 Years",{"count":574,"type":22},120,"2 Years","Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying individuals at risk before they develop symptoms of heart disease and start preventative treatment earlier.",[98,578],"Atherosclerotic Cardiovascular Disease (ASCVD)",[569],{"date":581,"type":43},"2026-07-14",{"date":583,"type":43},"2024-09-04",{"date":585,"type":22},"2028-03-04",{"name":587,"class":83},"Brigham and Women's Hospital",3,{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":4},"100647293","phase-2-the-effect-of-ginkgo-biloba-on-rheumatoid-arthritis-patients-100647293","NCT07709312","the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients","The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients","Inclusion Criteria:1. Adult patients (older than 18 years) 2. With moderate to high disease activity defined as DAS-28 score ≥ 3.2 3. Patients receiving stable regimen of one or more csDMARDs for the past 6 months\n\n\\-\n\nExclusion Criteria:\n\n\\- 1. Patients with known hypersensitivity to Ginkgo biloba 2. Patients receiving Ginkgo biloba for any other indications 3. Patients on biologic DMARDs 4. Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin), 5. Patients with any of the following comorbidities: congestive heart failure, history of myocardial infarction, severe anemia, active infections, other inflammatory diseases, and malignancies.\n\n6\\. Patients with other autoimmune diseases",{"count":597,"type":22},50,[26,120],"this study aims to measure The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients ,the outcomes are hsCRp,calprotectin,DAS-28,HAQ-DI",[30,601],"Manegmentof Rheumatoid Arthritis","2026-07-12",{"date":604,"type":43},"2026-07-16",{"date":606,"type":22},"2026-07-15",{"date":608,"type":22},"2026-10-15",{"name":434,"class":83},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":618,"targetDuration":4,"studyType":23,"phases":620,"briefSummary":621,"conditions":622,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":628,"locationsCount":84},"100646908","phase-2-a-phase-iia-study-of-jab-8263-in-patients-with-active-rheumatoid-arthritis-100646908","NCT07684157","A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis","A Phase Randomized, Double-blind, Placebo-controlled Evaluate the Efficacy and Safety IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis","JAB-8263","Inclusion Criteria:\n\n1. Age ≥18 years old and \\\u003C75 years old at the time of signing the informed consent form, regardless of gender;\n2. Active rheumatoid arthritis, ESR or C-reactive protein\\> upper limit of normal\n3. Meets the 2010 American College of Rheumatology ACR\u002FEULAR RA classification standards\n4. Participants have recovered from adverse reactions to previous antirheumatic treatment.\n\nExclusion Criteria:\n\n1. Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin;\n2. Use of NSAIDs within 1 week before first dose of investigational product\n3. Known or suspected allergies to the investigational product or any of its components;\n4. Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years);\n5. Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;",{"count":619,"type":22},32,[26],"This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK\u002FPD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.",[30],"2026-06-29",{"date":625,"type":43},"2026-07-06",{"date":356,"type":22},{"date":312,"type":22},{"name":629,"class":50},"Jacobio Pharmaceuticals Co., Ltd.",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":23,"phases":640,"briefSummary":641,"conditions":642,"keywords":643,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":658},"100645042","medical-device-for-sustained-remission-in-rheumatoid-arthritis-treated-with-biological-therapy-100645042","NCT07678112","Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy","Efficacy, Safety and Cost-effectiveness of a Biomarker-based Predictive Model for Persistent Remission in Rheumatoid Arthritis Patients Undergoing Biological Therapy Optimization","REMRABIT-Plus","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of rheumatoid arthritis according to either the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR\u002FEULAR classification criteria.\n* Clinical remission for at least 6 months prior to the baseline visit, defined as DAS28-CRP \\\u003C 2.6.\n* Receiving biological anti-TNF therapy (infliximab, adalimumab, etanercept, golimumab, or certolizumab).\n* Ability and willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients in whom biological therapy was prescribed due to systemic manifestations of rheumatoid arthritis.\n* Patients with rheumatoid arthritis and any known associated condition that may interfere with the assessment of study outcomes (e.g., fibromyalgia or concomitant chronic inflammatory diseases).\n* Patients receiving chronic anti-TNF biological therapy who are already undergoing treatment tapering or are on reduced or extended dosing regimens prior to study inclusion.",{"count":639,"type":22},184,[144],"This study aims to evaluate a new tool designed to help doctors decide whether it is safe to reduce medication in patients with rheumatoid arthritis (RA) who are in remission.\n\nRheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing pain, stiffness, and reduced mobility. Many patients receive long-term treatment with biological drugs to control the disease. When the disease is well controlled (remission), doctors may gradually reduce the medication dose. However, deciding when and in whom to reduce treatment is currently based on experience and trial-and-error.\n\nThe study evaluates a predictive tool (called OPTIBIO) that uses information from blood samples, genetic data, and clinical characteristics to estimate the risk that the disease will flare up if treatment is reduced.\n\nParticipants in the study will be randomly assigned to one of two groups:\n\n* In one group, the decision to reduce medication will be made by their usual doctor.\n* In the other group, the decision will be guided by the predictive tool.\n\nThe study lasts 12 months and includes several hospital visits. During these visits, participants will:\n\n* Answer questionnaires about their health and quality of life\n* Have physical examinations\n* Provide blood samples for routine tests and additional research purposes\n* Possibly undergo joint ultrasound (if they consent) Some additional blood samples may be stored in authorized biobanks for future research related to rheumatoid arthritis, but only if participants explicitly agree. These samples will be coded to protect personal identity and will only be used in ethically approved research projects.\n\nParticipation in the study is entirely voluntary. Participants can choose which procedures they agree to and may withdraw at any time without affecting their medical care.\n\nThe study may not provide direct benefit to participants, but it could help improve future treatment decisions and the overall management of rheumatoid arthritis.",[30],[255,644,645,646,647,648],"Treatment Optimization","TNF Inhibitors (TNFi)","Biologic Therapy","Personalized Medicine","Precision Medicine","2026-06-24",{"date":651,"type":43},"2026-07-01",{"date":653,"type":43},"2025-08-28",{"date":655,"type":22},"2027-08",{"name":657,"class":83},"Francisco J. Blanco",9,{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":531,"sex":18,"minAge":666,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":23,"phases":669,"briefSummary":670,"conditions":671,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":4},"100644969","phase-1-bioequivalence-study-of-ski-o-703-in-healthy-adults-under-fed-conditions-100644969","NCT07675226","Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions","An Open-label, Randomized, Fed, Single-dose, Oral Administration, 2-treatment, 2-period, Crossover Design, Phase 1 Clinical Trial to Evaluate the Bioequivalence of SKI-O-703 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Korean or Caucasian adults aged 19 years and older at screening. Caucasian: An individual whose parents and grandparents are of European, North American, or Middle Eastern origin; who was born in Europe, North America, or West Asia; and who has resided outside these regions for less than 10 years\n2. Body mass index (weight \\[kg\\] \u002F height2 \\[m\\]2) between 18 and 30 kg\u002Fm2, and body weight not less than 50 kg.\n3. Healthy on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening.\n4. Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel including liver enzymes, other specific tests, hematology, blood coagulation test, urinalysis or urine drug test are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents.\n5. Must sign voluntarily an informed consent form indicating they understand the purpose of, procedures required for, and comply to the prohibitions and restrictions specified in the study and is willing to participate in the study.\n\nExclusion Criteria:\n\n1. Any significant surgical\u002Fmedical procedure or trauma within 4 weeks before the planned first dose of the study drug or history of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair)\n2. Any current active infections, including localized infections, or any recent history (within 1 week prior to study drug administration) of active infections (including severe acute respiratory syndrome coronavirus 2 \\[SARS-CoV-2\\], cough or fever, or a history of recurrent or chronic infections).\n3. Unable to swallow multiple capsules by mouth.\n4. Received an experimental drug within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the first dose of the study drug is scheduled. Prior experience of participating in another clinical trial within 6 months before the planned first dose of the study drug.\n5. Individuals who have dietary habits that may influence the absorption, distribution, metabolism, or excretion of the investigational product or who consume foods known to affect drug metabolism.\n6. Before the start of the study (first day of administration) those who have donated whole blood or blood components within 8 weeks or within 2 weeks, respectively, or received a blood transfusion within 1 month, or cannot refrain from donating blood from the time of written consent until the end of the trial.\n7. History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening.\n8. Individual unable to abstain from alcohol-, caffeine-, or xanthine-containing products within 72 hours before the first dose of study drug and during the study or who tested positive for drug abuse, alcohol at screening or check-in (Day -1).\n\n10\\) Smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarrets, or inhalers) within 30 days before the first dose of study drug or who tested positive for cotinine(indicating active current smoking) at screening or check-in (Day -1) 11) Individuals with hypersensitive to investigational product or components of investigational product 12) A women who are pregnant or suspected of being pregnant or breastfeeding. 13) Participants who do not consent to use medically acceptable methods of contraception\\* to eliminate the possibility of pregnancy from the date of the first dose until 1 month after the last dose of the study drug.\n\n\\*Combined use of an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, tubal ligation, and barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or a combination of at least two barrier methods with spermicide.\n\n14\\) Individuals with hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.","19 Years",{"count":668,"type":22},48,[25],"This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions. Approximately 48 Korean and Caucasian participants will receive a single oral dose of the test drug and a single oral dose of the reference drug in a randomized sequence, separated by a washout period, with pharmacokinetic sampling and safety assessments performed throughout the study.",[672,673,30],"Bioequivalence Study in Healthy Subjects","Immune Thrombocytopenia (ITP)","2026-06-23",{"date":676,"type":43},"2026-06-30",{"date":678,"type":22},"2026-07-10",{"date":680,"type":22},"2026-12-31",{"name":682,"class":50},"Oscotec Inc."]